Certificates of supplementary protection (CSPs) are used as an extension of intellectual property rights, compensating pharmaceutical companies for the time between invention of a product and it entering the market. In effect, they extend the patent by a number of years. Health Canada announced three CSPs in June 2018:
- neisseria meningitidis grp B recombinant lipoprotein 2086 sub-family A/neisseria meningitidis group B recombinant lipoprotein 2086 sub-family B (Pfizer’s Trumenba);
- letermovir (Merck’s Prevymis);
- guselkumab (Tremfya)
These three products join a further four CSPs, with decisions pending on eight others.
Health Canada also made changes to their CSP application system, increasing their fees to C$9,192.